What is HC Wainwright’s Estimate for DTIL FY2024 Earnings?

Precision BioSciences, Inc. (NASDAQ:DTIL) – Research analysts at HC Wainwright dropped their FY2024 EPS estimates for Precision BioSciences in a research report issued on Tuesday, November 5th. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings per share of ($1.23) for the year, down from their prior forecast of $0.82. HC Wainwright currently has a “Buy” rating and a $60.00 target price on the stock. The consensus estimate for Precision BioSciences’ current full-year earnings is $0.82 per share. HC Wainwright also issued estimates for Precision BioSciences’ Q4 2024 earnings at ($0.42) EPS, Q1 2025 earnings at ($0.38) EPS and FY2025 earnings at ($1.05) EPS.

Precision BioSciences Trading Down 0.7 %

Shares of DTIL stock opened at $8.40 on Thursday. The firm’s fifty day moving average price is $9.31 and its two-hundred day moving average price is $10.05. Precision BioSciences has a 1 year low of $7.97 and a 1 year high of $19.43. The firm has a market capitalization of $60.77 million, a P/E ratio of 140.00 and a beta of 1.71.

Institutional Trading of Precision BioSciences

A hedge fund recently bought a new stake in Precision BioSciences stock. Janus Henderson Group PLC acquired a new position in shares of Precision BioSciences, Inc. (NASDAQ:DTIL) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 573,052 shares of the company’s stock, valued at approximately $7,739,000. Janus Henderson Group PLC owned approximately 8.29% of Precision BioSciences as of its most recent SEC filing. Institutional investors and hedge funds own 37.99% of the company’s stock.

About Precision BioSciences

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.